ABOUT BIOFRONTERA

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs.
The Germany-based company develops and markets innovative products for the treatment of the skin.

The company's lead product is Ameluz^®, a topical prescription drug used for photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz^® has been marketed in the EU since 2012.

Biofrontera is one of the first German biopharmaceutical companies to receive a centralized European and a UK-approval for a drug developed in-house. 

The Biofrontera Group was founded in 1997 and is listed on the Frankfurt Stock Exchange (Prime Standard).